Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients
Related Experiment Video
Updated: Jun 25, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
1Division of Nephrology, Salem Veterans Affairs Medical Center, Salem, VA 24153, USA. csaba.kovesdy@va.gov
Insights
Iron management in chronic kidney disease (CKD) is shifting towards addressing iron deficiency. This review explores the link between iron levels and patient outcomes, especially in non-dialysis CKD.
Area of Science:
- Nephrology
- Hematology
- Epidemiology
Background:
- Abnormal iron homeostasis is central to anemia in chronic kidney disease (CKD).
- Historically, iron overload was common, but relative iron deficiency is now more prevalent in CKD patients.
- Current iron management targets specific markers like transferrin saturation and serum ferritin.
Purpose of the Study:
- To review iron homeostasis and long-term clinical outcomes in CKD from an epidemiologic viewpoint.
- To define ideal therapeutic strategies for iron management in clinical practice.
- To identify areas for future research, particularly in non-dialysis-dependent CKD patients.
Main Methods:
- Literature review focusing on epidemiologic data.
- Analysis of studies examining iron markers and clinical outcomes.
- Consideration of specific challenges in non-dialysis-dependent CKD.
Main Results:
- The clinical benefit of achieving target iron store markers in CKD remains uncertain.
- Iron deficiency is a significant concern in contemporary CKD populations.
- Management of iron in non-dialysis CKD presents unique challenges.
Conclusions:
- Further research is needed to link iron marker targets to improved clinical outcomes in CKD.
- Optimizing iron management strategies is crucial for patient care.
- Specific attention to non-dialysis-dependent CKD is warranted for effective iron therapy.
Abstract:
Abnormal iron homeostasis plays an important role in the anemia of chronic kidney disease (CKD). Although iron overload was the main complication seen in the pre-erythropoiesis-stimulating agent era, relative iron deficiency is much more common today in patients with CKD. Maintaining certain "desirable" levels of commonly used markers of iron stores (such as transferrin saturation ratio and serum ferritin) have become the goal of iron management in clinical practice, yet it is unclear whether achievement and maintenance of these "desirable" levels translates into improved clinical outcomes. This review examines issues related to iron and long-term clinical outcomes from an epidemiologic perspective, with the goal to determine what an ideal therapeutic approach should be in clinical practice and what future research is required to clarify important practical questions. Particular attention is devoted to patients with non-dialysis-dependent CKD because the management of iron homeostasis in this group of patients poses additional intriguing questions.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...